FDA to review use of surufatinib for the treatment of advanced neuroendocrine tumours (NET) via a rolling review

In the phase III SANET-ep trial surufatinib reduced the risk of progression or death by 67%, in non-pancreatic NET patients. Fast track designation had been previously granted for this oral angio-immuno kinase inhibitor.

Source:

Biospace Inc.